News

Kapil Mishra, MD, discusses an overview of radiation retinopathy and its challenges in treating uveal melanoma from his presentation "Radiation Retinopathy: Future Strategies,"

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

At ARVO 2025, in Salt Lake City, Utah, Diana Do, MD, gave an update on the LIGHTSITE III study of photobiomodulation for dry age-related macular degeneration.

Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.

Duke professor Sharon Fekrat, MD, discusses AI-driven ophthalmology with smartphone diagnostics and robotic procedures, emphasizing global collaboration and innovative medical research.

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in geographic atrophy patients, highlighting early intervention opportunities.

Christina Prescott, MD, talks about the rate of recurrence of stromal keratitis in the Zoster Eye Disease Study, both in the placebo and in the treatment group.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients.

Alfredo Sadun, MD, PhD, details a fascinating outcome from a gene therapy in development for Leber hereditary optic neuropathy.

Perfluorohexyloctane demonstrated rapid symptom relief in patients with dry eye, with effects reported as early as 5 minutes after dosing.

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

The biomarkers are especially crucial for patients with lupus nephritis.

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.

Nationwide recall of over 70,000 eye care products due to safety risks prompts consumers to return items for full credit.

CCOI transforms ophthalmic innovation by uniting stakeholders, streamlining processes, and prioritizing patient perspectives for faster, impactful solutions.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

The biomarkers are especially crucial for patients with lupus nephritis

Discover how real-world evidence shapes cataract surgery practices, highlighting user satisfaction with enhanced monofocal IOLs at the 2025 ASCRS Annual Meeting.

Almeida highlighted the increasing prevalence of diabetic macular edema and the importance of developing safe, well-tolerated treatments.

Carl D. Regillo, MD, shares insights on the VERONA trial of EYP-1901 at the Retina World Congress 2025 meeting held in Fort Lauderdale, Florida.